BidaskClub Upgrades Omnicell (NASDAQ:OMCL) to “Buy”

Omnicell (NASDAQ:OMCL) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Saturday, BidAskClub reports.

OMCL has been the topic of several other research reports. Piper Sandler lowered their price objective on shares of Omnicell from $76.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 29th. Cantor Fitzgerald raised their price objective on shares of Omnicell from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Craig Hallum lowered their price objective on shares of Omnicell from $102.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Finally, Stephens began coverage on shares of Omnicell in a research note on Monday, July 6th. They issued an “overweight” rating and a $90.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $85.50.

Shares of OMCL stock opened at $77.12 on Friday. Omnicell has a 12 month low of $54.24 and a 12 month high of $94.85. The business’s 50 day moving average is $69.75 and its two-hundred day moving average is $68.77. The company has a market cap of $3.30 billion, a PE ratio of 68.25, a price-to-earnings-growth ratio of 3.24 and a beta of 0.93.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, July 28th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.23 by $0.14. The company had revenue of $199.62 million for the quarter, compared to the consensus estimate of $182.16 million. Omnicell had a return on equity of 9.21% and a net margin of 5.42%. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 earnings per share. On average, sell-side analysts expect that Omnicell will post 1.48 earnings per share for the current fiscal year.

In other Omnicell news, CEO Randall A. Lipps sold 3,718 shares of Omnicell stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $75.15, for a total transaction of $279,407.70. Following the completion of the transaction, the chief executive officer now directly owns 152,116 shares of the company’s stock, valued at $11,431,517.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Randall A. Lipps sold 1,400 shares of Omnicell stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $75.01, for a total value of $105,014.00. Following the transaction, the chief executive officer now directly owns 152,116 shares of the company’s stock, valued at $11,410,221.16. The disclosure for this sale can be found here. 2.63% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Ensign Peak Advisors Inc lifted its holdings in shares of Omnicell by 0.6% during the first quarter. Ensign Peak Advisors Inc now owns 32,900 shares of the company’s stock valued at $2,158,000 after acquiring an additional 200 shares during the period. Torray LLC raised its holdings in shares of Omnicell by 1.8% in the second quarter. Torray LLC now owns 13,042 shares of the company’s stock valued at $921,000 after buying an additional 229 shares during the last quarter. Magnus Financial Group LLC raised its holdings in shares of Omnicell by 7.4% in the second quarter. Magnus Financial Group LLC now owns 3,906 shares of the company’s stock valued at $276,000 after buying an additional 268 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in shares of Omnicell by 930.8% in the first quarter. Meeder Asset Management Inc. now owns 402 shares of the company’s stock valued at $26,000 after buying an additional 363 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of Omnicell by 0.6% in the first quarter. Alliancebernstein L.P. now owns 70,046 shares of the company’s stock valued at $4,594,000 after buying an additional 393 shares during the last quarter. 98.99% of the stock is owned by institutional investors.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Further Reading: What impact do institutional investors have on markets?

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.